BenzingaAugust 7, 2026 at 3:07 AM NY28 days ago

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $35 to $30.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story